Kynam Capital Management, LP Celldex Therapeutics, Inc. Transaction History
Kynam Capital Management, LP
- $1.22 Billion
- Q3 2024
A detailed history of Kynam Capital Management, LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Kynam Capital Management, LP holds 3,458,609 shares of CLDX stock, worth $86.9 Million. This represents 9.64% of its overall portfolio holdings.
Number of Shares
3,458,609
Previous 3,388,967
2.05%
Holding current value
$86.9 Million
Previous $125 Million
6.33%
% of portfolio
9.64%
Previous 9.76%
Shares
12 transactions
Others Institutions Holding CLDX
# of Institutions
207Shares Held
67.3MCall Options Held
1.69MPut Options Held
980K-
Wellington Management Group LLP Boston, MA9.24MShares$232 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$118 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$97.3 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$83.8 Million1.99% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.07MShares$77.2 Million1.76% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.18B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...